Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2014

View Archived Issues

Novel biomarkers of cardiovascular injury and disease presented at the ACC meeting

New NHE-1 inhibitor to prevent cardiovascular disease-related reperfusion injury

Hepatera begins pilot study of Myrcludex B in HDV

Defense Department grant funds gene therapy study for ALS

U.S. proof-of-concept study of Glassia begins in GVHD

Astellas submits MAA for Xtandi for chemotherapy-naive mCRPC

Adempas approved in the E.U. for two life-threatening forms of pulmonary hypertension

Regado Biosciences extends enrollment in phase III trial of REG-1

Allegro Diagnostics reports results from BronchoGen genomic test trial

MDxHealth and LI PATH enter into marketing agreement for ConfirmMDx

First patient enrolled in phase III trial of clonidine gel for diabetic neuropathy

Rosetta Genomics and Marina Biotech to develop microRNA products for rare diseases

Cepheid confirms launch of Xpert HPV, a rapid test for cervical cancer-related HPV

NICE recommends the exhaled nitric oxide testing to diagnose and manage asthma

Reata Pharmaceuticals reports discovery of NO production inhibitors

Qbtech launches FDA-cleared ADHD test

Mitsubishi Tanabe Pharma and Shanghai Pharmaceuticals jointly present novel renin inhibitors

Australian researchers report development of ICMT inhibitors

Eternity Bioscience prepares new B-raf inhibitors

Study of RO-5186582 enrolling subjects with Down syndrome

Gilead Sciences reports data from phase III study of sofosbuvir in HCV in Japan

Researchers identify potential biomarker of mitochondrial dysfunction in acute kidney injury

FDA clears IND for OMS-721 in thrombotic microangiopathies

Janssen begins phase III OPTIMIST trials of simeprevir in combination with sofosbuvir

Cytonet's liver cell therapy shows benefit in patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...